Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof

• US 20060034889A1
• Filed: 08/16/2004
• Published: 02/16/2006
• Est. Priority Date: 08/16/2004
• Status: Abandoned Application

• Current Assignee: Protherics Salt Lake City, Inc.
• Original Assignee: Macromedia Incorporated (Protherics Incorporated)
• Inventors: Jo, Seongbong, Piao, Ai-Zhi
• Application Number:
  US10/919,603
• Publication Number:
  US 20060034889A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/256 Antibodies, e.g. immunoglobulins, vaccines
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/43 Hormones, e.g. dexamethasone
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: C08G 63/664 derived from hydroxy carboxylic acids
• CPC Class Codes: C08G 64/183 containing polyether sequences
• CPC Class Codes: C08L 2666/02 Organic macromolecular compounds, natural resins, waxes or and bituminous materials
• CPC Class Codes: C08L 53/00 Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
• CPC Class Codes: C08L 53/005 Modified block copolymers

Abstract

A water soluble, biodegradable AB type diblock copolymer which comprises 61 to 85% by weight of a biodegradable, hydrophobic A block comprising a biodegradable polyester, and 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight less than 5000, and wherein said diblock copolymer has a number average molecular weight less than 15000 and possesses reverse thermal gelation properties.

Claims

1. A biodegradable AB type diblock copolymer comprising:

i) 61 to 85% by weight of a biodegradable, hydrophobic A block which is a member selected from the group consisting of biodegradable polyesters, biodegradable polyester amides, biodegradable polyether esters, biodegradable polyurethanes, biodegradable polyester urethanes, biodegradable polycarbonates and polyester carbonates; and

ii) 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight within a range of 50 Daltons to 5000 Daltons,

wherein said diblock copolymer has a number average molecular weight within a range of 450 Daltons to 15000 Daltons and possesses reverse thermal gelation properties.

2. The diblock copolymer according to claim 1, wherein the biodegradable, hydrophobic A block is synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, p-dioxanone, trimethylene carbonate, ε

-caprolactone, ε

-hydroxy hexonoic acid, γ

-butyrolactone, γ

-hydroxy butyric acid, δ

-valerolactone, δ

-hydroxy valeric acid, hydrooxybutyric acids, malic acid, and copolymers thereof.

3. The diblock copolymer according to claim 1 wherein, in the diblock polymer, each hydrophobic A block has a number average molecular weight of between 500 Daltons and 5000 Daltons and each hydrophilic B block has a number average molecular weight of between 350 Daltons and 2000 Daltons.

4. The diblock copolymer according to claim 3 wherein, in the diblock polymer, each hydrophobic A block has a number average molecular weight of between 1000 Daltons and 4000 Daltons and each hydrophilic B block has a number average molecular weight of between 500 Daltons and 800 Daltons.

5. An aqueous biodegradable polymeric drug delivery composition possessing reverse thermal gelation properties comprised of an aqueous phase having uniformly contained therein:

(a) an effective amount of a drug; and

(b) a biodegradable AB type diblock copolymer comprising;

i) 61 to 85% by weight of a biodegradable, hydrophobic A block which is a member selected from the group consisting of biodegradable polyesters, biodegradable polyester amides, biodegradable polyether esters, biodegradable polyurethanes, biodegradable polyester urethanes, biodegradable polycarbonates and polyester carbonates; and

ii) 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight within a range of 50 Daltons to 5000 Daltons,

wherein said diblock copolymer has a number average molecular weight within a range of 450 Daltons to 15000 Daltons and possesses reverse thermal gelation properties.

6. The aqueous polymeric composition according to claim 5 wherein the diblock polymer content of said composition is between 3 and 50% by weight.

7. The aqueous polymeric composition according to claim 5 wherein the biodegradable, hydrophobic A block is synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ε

-caprolactone, ε

-hydroxy hexonoic acid, γ

-butyrolactone, γ

-hydroxy butyric acid, δ

-valerolactone, δ

-hydroxy valeric acid, hydrooxybutyric acids, malic acid, and copolymers thereof.

8. The aqueous polymeric composition according to claim 5 wherein, in the diblock copolymer, each hydrophobic A block has a number average molecular weight of between 500 Daltons and 5000 Daltons and each hydrophilic B block has a number average molecular weight of between 350 Daltons and 2000 Daltons.

9. The diblock copolymer according to claim 8 wherein, in the diblock polymer, each hydrophobic A block has a number average molecular weight of between 1000 Daltons and 4000 Daltons and each hydrophilic B block has a number average molecular weight of between 500 Daltons and 800 Daltons.

10. The aqueous polymeric composition according to claim 5 wherein said drug is a member selected from the group consisting of polypeptides, proteins, nucleic acids, genes, hormones, anticancer agents, anti-cell proliferation agents and cells for transplantation.

11. The aqueous polymeric composition according to claim 10 wherein said polypeptide or protein is a member selected from the group consisting of oxytocin, vasopressin, adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, growth hormone (human, porcine, bovine, etc.), growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin-2 (IL-2), interferon-α

,β

, or γ

, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), interleukin-11 (IL-11), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogues, modifications and pharmacologically active fragments thereof, enzymes, cytokines, antibodies and vaccines.

12. The aqueous polymeric composition according to claim 5 wherein the drug content of said composition is between 0.01 and 20% by weight.

13. The aqueous polymeric composition according to claim 10 wherein said vaccine is a member selected from the group consisting of hepatitis vaccine, synthetic analogues, modifications and pharmacologically active fragments thereof.

14. The aqueous polymeric composition according to claim 10 wherein said hormone is a member selected from the group consisting of testosterone, estradiol, progesterone, prostaglandins, synthetic analogues, modifications and pharmaceutical equivalents thereof.

15. The aqueous polymeric composition according to claim 10 wherein said drug is an anticancer agent selected from the group consisting of mitomycin, bleomycin, BCNU, carboplatin, doxorubicin, daunorubicin, methotrexate, paclitaxel, taxotere, actinomycin D, camptothecin, synthetic analogues, modifications and pharmaceutical equivalents thereof.

16. A method for the administration of a drug to a warm-blooded animal in a controlled release form which comprises:

(1) providing an aqueous biodegradable polymeric drug delivery composition possessing reverse thermal gelation properties comprised of an aqueous phase having uniformly contained therein;

(a) an effective amount of a drug; and

(b) a biodegradable AB type diblock copolymer comprising;

i) 61 to 85% by weight of a biodegradable, hydrophobic A block which is a member selected from the group consisting of biodegradable polyesters, biodegradable polyester amides, biodegradable poly ether esters, biodegradable polyurethanes, biodegradable polyester urethanes, biodegradable polycarbonates and polyester carbonates; and

ii) 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight within a range of 50 Daltons to 5000 Daltons, and wherein said diblock copolymer has a number average molecular weight within a range of 450 Daltons to 15000 Daltons and possesses reverse thermal gelation properties;

(2) maintaining said composition as a liquid at a temperature below the gelation temperature of said diblock copolymer; and

(3) administering said composition as a liquid to said warm-blooded animal with the subsequent formation of a gel as the temperature of said composition is raised by the body temperature of said animal to above the gelation temperature of said diblock polymer.

17. The method according to claim 16 wherein said administration is by parenteral, ocular, topical, inhalation, transdermal, vaginal, buccal, transmucosal, transurethral, rectal, nasal, oral, pulmonary or aural means.

18. The method according to claim 16 wherein the diblock copolymer content of said composition is between 3 and 50% by weight.

19. The method according to claim 16 wherein the biodegradable, hydrophobic A block is synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, p-dioxanone, trimethylene carbonate, ε

-caprolactone, ε

-hydroxy hexonoic acid, γ

-butyrolactone, γ

-hydroxy butyric acid, δ

-valerolactone, δ

-hydroxy valeric acid, hydrooxybutyric acids, malic acid, and copolymers thereof.

20. The method according to claim 16 wherein, in the diblock polymer, each hydrophobic A block has a number average molecular weight of between 500 Daltons and 5000 Daltons and each hydrophilic B block has a number average molecular weight of between 350 Daltons and 2000 Daltons.

21. The diblock copolymer according to claim 20 wherein, in the diblock polymer, each hydrophobic A block has a number average molecular weight of between 1000 Daltons and 4000 Daltons and each hydrophilic B block has a number average molecular weight of between 500 Daltons and 800 Daltons.

22. The method according to claim 16 wherein said drug is a member selected from the group consisting of polypeptides, proteins, nucleic acids, genes, hormones, anticancer agents, anti-cell proliferation agents and cells for transplantation.

23. The method according to claim 22 wherein said polypeptide or protein is a member selected from the group consisting of oxytocin, vasopressin, adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, growth hormone (human, porcine, bovine, etc.), growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin-2 (IL-2), interferon-α

,β

, or γ

, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), interleukin-11 (IL-11), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogues, modifications and pharmacologically active fragments thereof, enzymes, cytokines, antibodies and vaccines.

24. The method according to claim 16 wherein the drug content of said composition is between 0.01 and 20% by weight.

25. The method according to claim 22 wherein said vaccine is a hepatitis vaccine, or synthetic analogues, modifications and pharmacologically active fragments thereof.

26. The method according to claim 22 wherein said hormone is a member selected from the group consisting of testosterone, estradiol, progesterone, prostaglandins, synthetic analogues, modifications and pharmaceutical equivalents thereof.

27. The method according to claim 22 wherein said drug is an anticancer agent selected from the group consisting of mitomycin, bleomycin, BCNU, carboplatin, doxorubicin, daunorubicin, methotrexate, paclitaxel, taxotere, actinomycin D, camptothecin, synthetic analogues, modifications and pharmaceutical equivalents thereof.

28. A method for enhancing the solubility of a drug, comprising uniformly admixing an effective amount of said drug in an aqueous biodegradable polymeric drug delivery composition possessing reverse thermal gelation properties, said aqueous composition being comprised of an aqueous phase having uniformly contained therein a biodegradable AB type diblock copolymer comprising:

i) 61 to 85% by weight of a biodegradable, hydrophobic A block which is a member selected from the group consisting of biodegradable polyesters, biodegradable polyester amides, biodegradable polyether esters, biodegradable polyurethanes, biodegradable polyester urethanes, biodegradable polycarbonates and polyester carbonates; and

ii) 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight within a range of 50 Daltons to 5000 Daltons,

wherein said diblock copolymer has a number average molecular weight within a range of 450 Daltons to 15000 Daltons and possesses reverse thermal gelation properties.

29. A method for enhancing the stability of a drug comprising uniformly admixing an effective amount of said drug in an aqueous biodegradable polymeric drug delivery composition possessing reverse thermal gelation properties said aqueous composition being comprised of an aqueous phase having uniformly contained therein a biodegradable AB type diblock copolymer comprising:

i) 61 to 85% by weight of a biodegradable, hydrophobic A block which is a member selected from the group consisting of biodegradable polyesters, biodegradable polyester amides, biodegradable polyether esters, biodegradable polyurethanes, biodegradable polyester urethanes, biodegradable polycarbonates and polyester carbonates; and

ii) 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight within a range of 50 Daltons to 5000 Daltons,

wherein said diblock copolymer has a number average molecular weight within a range of 450 Daltons to 15000 Daltons and possesses reverse thermal gelation properties.